Despite combination antiretroviral therapies (cART), a significant proportion of HIV-infected patients develop HIV-associated neurocognitive disorders (HAND).
Introduction
The widespread use of combination antiretroviral therapy (cART) dramatically decreased the mortality rate of HIV-infected individuals, and decreased the incidence of HIV-associated dementia (HAD (Heaton et al., 2011) . Although cART decreased the incidence HAD, it appears to have had little impact on the prevalence of milder forms of cognitive impairments that are collectively known as HIV-Associated Neurocognitive Disorders (HAND) (Heaton et al., 2010; Letendre et al., 2010; McArthur et al., 2010; Heaton et al., 2011; Valcour et al., 2011b) . Currently available data suggests that 50% of HIV-infected subjects will develop a neurologic disorder Ernst and Chang, 2004; Valcour et al., 2004; Chang et al., 2008; Valcour et al., 2011a) . Moreover, the occurrence of HAND is associated with an increased risk of death (Vivithanaporn et al., 2010) . Although the mechanism(s) for this residual cognitive impairment and association with increased mortality are not completely understood, continued viral replication in the brain due to insufficient central nervous system (CNS) penetration of cART is though to be an underlying mechanism (Robertson et al., 2007) . Therefore, cART regimens with increased brain penetration have been proposed to combat HAND (Letendre et al., 2008) . While there is evidence that this approach reduces CSF viral load (Marra et al., 2009 ) and may improve cognitive function (Letendre et al., 2004; Smurzynski et al., 2011) , there is also evidence that some antiretroviral drugs (ARVs) are toxic to neurons (Liner et al., 2010) , and that ARVs with increased brain penetration are associated with poor cognitive performance (Tozzi et al., 2007; Marra et al., 2009) . Therefore, the JPET #195701 6 effectiveness of brain penetrating cART regimens is currently in question (Koopmans et al., 2009 ).
Few studies have directly determined the effects of antiretroviral drugs on neuronal function (Schweinsburg et al., 2005; Cardenas et al., 2009) , and no studies have determined potential neurotoxic effects of antiretroviral drug metabolites. Most xenobiotics are metabolized by the cytochrome P450 (CYP) superfamily of enzymes that catalyze Phase 1 reactions (oxidation, reduction, hydrolysis). CYPs are concentrated in liver, but are also expressed in brain (Gervot et al., 1999; Bhagwat et al., 2000; Miksys et al., 2003) . CNS effects of the non-nucleoside reverse transcriptase inhibitor Efavirenz ((S)-(-)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one; EFV), have been reported that include sleep disturbances, cognitive and mood disorders (Marzolini et al., 2001; Perez-Molina, 2002; Lochet et al., 2003; Rihs et al., 2006) , but to date there are no studies that have directly determined the effects of EFV or its metabolites on neuronal function. EFV is metabolized primarily by CYP2B6 to produce a series of metabolites of which 8-hydroxyefavirenz (8-OH-EFV) is the most abundant (Ward et al., 2003; Bumpus et al., 2006; Ogburn et al., 2010) . In this study we provide evidence that 8-OH-EFV is a potent neurotoxin that dysregulates neuronal calcium homeostasis, and damages dendritic spines in the low nM range. The effects of this metabolite are distinct from the parent drug, and highlight the importance of screening not only antiretroviral medications for neurotoxicity, but also drug metabolites.
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METHODS
Human Plasma and CSF. Paired plasma and CSF samples were obtained from 13 HIV-infected subjects enrolled in the North Eastern AIDS Dementia (NEAD) study (Sacktor et al., 2002) . All subjects were taking cART regimens that included EFV. Subjects consisted of 10 males and 3 females aged 49.23 ± 10.35 years. CD4+ cell counts in this population were 369.6 ± 110.1 cells/mm 3 . HIV was detectable in plasma of 3 subjects, and in CSF of 4 subjects.
Production and isolation of 7-hydroxy and 8-hydroxy efavirenz. P450 2A6 and P450 2B6 cDNAs were co-transformed and expressed with cytochrome P450 reductase in Escherichia coli to produce active P450s (Locuson et al., 2009 ). EFV (50 µM) was incubated with the membrane preparation for 60 min followed by termination of the reaction using acetonitrile. The samples were spun at 4000 x g for 10 min at 4ºC, supernatant was removed, and the metabolites purified by high pressure liquid chromatography (HPLC) using a Beckman Coulter 4.6 x 250 mm C18 HPLC column. The mobile phase consisted of water 0.1% formic acid (mobile phase A) and acetonitrile 0.1% formic acid (mobile phase B) using a gradient of 55% to 70% B over 24 min.
Following collection of the metabolite containing fractions, the samples were lyophilized and weighed. Methanol was then added to reconstitute the sample such that a 1% 8-hdyroxyefavirenz or 7-hydroxyefavirenz solution was produced.
The absorbance of a 1-cm layer of the solution at 247 nm was then measured.
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The amount of 8-hydroxyefavirenz was calculated using a molar absorptivity value of 46.5 (specific absorbance: A(1%, 1cm) = 465) and 48.3 (specific absorbance: A(1%, 1cm) = 483) for 7-hydroxyefavirenz.
Quantification of EFV, 7-OH-EFV and 8-OH-EFV. Sample preparation has been previously described (Avery et al., 2010) . Briefly, a racemic fluorinated analog of EFV (F-EFV; 10 ng) was added to 50 µl of sample prior to extraction for use as an internal standard. Extraction was conducted using a liquid: liquid method with a 1:1 mixture of hexane and ethyl acetate containing ammonium formate (50 mM). The organic layer was dried and reconstituted in 100 µl of methanol. A fraction of 5 µl was subjected to ultra high performance liquid chromatography tandem mass spectrometry (UPLC-MS-MS) using an AB Sciex QTRAP 5500 mass spectrometer (Foster City, CA) interfaced with an Acquity UPLC equipped with sample and binary solvent managers (Waters, Milford, MA).
EFV, 7-OH-EFV, 8-OH-EFV and F-EFV were resolved with a Waters XTerra MS C18, 2.5 µm, 21x50 mm column at a flow rate of 0.5 ml/min using gradient elution of mobile phase A (water, 0.1 % formic acid) to B (acetonitrile, 0.1 % formic acid).
Detection was performed in negative ion ESI mode via multiple reaction monitoring (MRM). The following MRM transitions were employed for quantification: m/z 314.0>244.1 (EFV), m/z 329.9>162.0 (8-OH-EFV), m/z 329.9 > 188.9 (7-OH-EFV) m/z 298.0>227.9 (F-EFV). A standard curve was run to simultaneously quantify EFV, 7-OH-EFV and 8-OH-EFV, with a lower quantification limit of 0.5 ng/ml.
JPET #195701 9
Cell Culture. Hippocampal neuronal cultures were prepared from embryonic day 18 Sprague Dawley rats using methods that have been described previously (Wheeler et al., 2009; Xu et al., 2011) . In brief, Hippocampi were isolated, trypsinized and cells were dissociated by tituration in a calcium-and magnesiumfree Hank's balanced salt solution. Neurons were plated at a density of 150,000 cells/ml on 15 mm diameter polyethylenimine coated glass coverslips in Neurobasal media supplemented with B-27 (Invitrogen, Carlsband CA) and 1% antibiotic solution (10 4 U of penicillin G/ml, 10 mg streptomycin/ml and 25 µg amphotericin B/ml)(Sigma). Three hours after plating, total media was replaced and thereafter was supplemented with Neurobasal media containing B-27 every were converted to nM [Ca 2+ ] c by curve fitting using reference standards as previously described (Wheeler et al., 2009 ).
Cell survival. Cell viability was determined by nuclear morphology using the fluorescent DNA binding dye Hoescht 33342 as described previously (Haughey et al., 2001 ). Nuclei were visualized on a Ziess Axiovert 200 inverted microscope (Carl Zeiss microscopy Thornwood NY) under epilfuorescence illumination (340 nm excitation and 510 nm barrier filter) using a 40 X oil immersion objective. Two hundred cells from 5 fields in 3 separate cultures per experimental condition were counted without knowledge of the experimental condition. Cells in which nuclear staining was diffuse were considered viable and cells where nuclear staining was condensed or fragmented were considered "apoptotic".
Imaging and quantification of dendritic spines. Dendritic spines were visualized by staining F-actin with phalloidin conjugated to Alexa 568. Neurons were washed once with PBS and fixed with ice-cold 4% PFA for 20 min. Cells were then washed with PBS containing 100 mM glycine, and incubated for 5 min in PBS containing 0.1% Triton X-100, and incubated with phalloidin 568 (5U/ml)
for 30 min at room temperature. Coverslips were washed twice with PBS to remove excess probe, and mounted on glass slides using a permanent mounting medium containing anti-fading agents (Vectashield). Dendritic branches were visualized using a Ziess Axiovert 200 inverted microscope (Carl Zeiss microscopy) equipped with an Orca CCD camera (Hamamatsu Photonics) under epilfuorescence illumination (558 nm excitation and 568 nm emission) using a 100 X oil objective.
A minimum of ten neurons from three independent experiments was analyzed for each condition. The number of dendritic spines (defined as thin protrusions emerging from dendritic processes) extending from 2-5 primary dendrites/neuron was quantified for a distance of approximately 20 μm from the cell soma using AxioVision 4.8.2 (Carl Zeiss Inc). Spine density across all measured dendritic segments was normalized to the length of the primary dendrite. Measurements were conducted by an investigator blinded to the experimental condition (D.G.).
RESULTS
The 8-hydroxyefavirenz metabolite evokes calcium influx in neurons.
EFV and the 7-OH-EFV and 8-OH-EFV metabolites used for these studies were isolated by HPLC-fractionation and the structures confirmed using mass spectrometry and NMR according to published spectral information (Mutlib et al., 1999) (Fig 1) . We first investigated whether EFV or its hydroxylated metabolites could alter intracellular Ca 2+ homeostasis in primary rat hippocampal neurons.
Two-minute applications of EFV (10 μM), or 7-OH-EFV (10 μM) had no effect on intracellular calcium (Fig 2A-C) . However, applications of 8-OH-EFV (10 μM)
induced immediate increases of intraneuronal Ca 2+ (Fig 2D) . With a 10 μM dose of 8-OH-EFV, approximately half of the neurons appeared undergo a catastrophic loss of membrane integrity and release of the calcium probe. The remaining neurons exhibited clear signs of damage including beading of neurites and vacuolization of the soma (data not shown). We then conducted a dose response for 8-OH-EFV (0.1-10 μM) and found that 1 μM was the minimum effective dose to consistently increase intraneuronal Ca 2+ (Fig 2E) within 1-5 sec of application (Fig 2E inset) . Applications of 8-OH-EFV induced the entry of calcium from an extracellular source, since the removal calcium from the buffer blocked this effect (Fig 2F, G) .
To determine the mechanism of Ca 2+ influx we used pharmacological inhibitors to block the major calcium permeable ion channels in neurons including NMDA (MK-801; 20 μM), AMPA (NBQX; 20 μM), purinergic (PPADS; 10 μM and Suramin; 100 μM), or voltage-gated calcium channels (VOCC; nifedipine; 10 μM) JPET #195701 13 and exposed neurons to 8-OH-EFV (1 μM; Fig 3A) . Blockade of NMDA or AMPA receptors had no effects on 8-OH-EFV-induced calcium influx (Fig 3B-C) .
Blockade of purinergic receptors (Fig 3D, E) , or VOCC (Fig 3F) each partially reduced 8-OH-EFV-evoked calcium influx. Blocking both purinergic receptors and VOCC slowed the rise of intraneuronal Ca 2+ that followed 8-OH-EFV exposures, but resulted in a similar peak level within 100 sec. compared with either drug alone ( Figure 3G ).
8-hydroxyefavirenz is potent neurotoxin.
We exposed primary neuronal cultures to EFV, 7-OH-EFV, or 8-OH-EFV (0.01-10 μM) for 24 h and determined apoptosis by nuclear morphology using the fluorescent DNA binding dye Hoescht 33342. The dose-response relationships for EFV and 7-OH-EFV were similar, with each compound exhibiting a minimum toxic dose of 0.1 μM that produced 41.3 ± 14.0% (EFV), and 41.2 ± 15.0 % (7-OH EFV) increases in apoptotic nuclei (Fig 4) . At the highest dose tested (10 μM)
EFV produced a 66.6 ± 4.2% and 7-OH-EFV produced a 63.5 ± 12.2 % increase in apoptotic nuclei (Fig 4A) In contrast, 8-OH-EFV was at-least an order of magnitude more toxic, and increased the percent of apoptotic nuclei to 36.4% ± 7.1% at a 0.01 μM dose (Fig 4A) . Neurotoxicity induced by 8-OH-EFV was not prevented by inhibition of purinergic receptors with PPADS (37.9 ± 11.8 % death), but was partially prevented by inhibition of L-type VOCCs (24.5 ± 8.0 % death). Inhibition of both purinergic receptors and L-type VOCCs did not further improve neuronal survival (27.6 ± 8.0; Fig. 4B ).
We next determined if low concentrations of EFV, or its hydroxylated metabolites (0.01 and 0.1 μM) damaged dendritic spines. EFV and the metabolites 7-OH-EFV and 8-OH-EFV each produced considerable loss of dendritic spines at a 0.1 μM dose. In control conditions there were 9.5 ± 0.9 secondary dendrites per 10 μm. Spine density was reduced to 4.0 ± 1.4 for EFV, 4.9 ± 1.5 for 7-OH-EFV, and to 4.7 ± 1.6 for 8-OH-EFV with a 0.1 μM dose. In contrast, the 8-OH metabolite of EFV was considerably more toxic, and reduced the number of dendritc spines to 5.2 ± 1.7 per 10 μm at a dose of 0.01 μM ( Fig   5B) . EFV and 7-OH-EFV at the dose of 0.001 μM did not appreciably alter the number of dendritic spines (Fig 5A) . Blockade of purinergic receptors with PPADS did not rescue dendritic spine damage induced by 8-OH-EFV (5.2 ± 2.0 per 10 μm), while inhibition of L-type VOCCs with nifedipine partially protected from 8-OH-EFV induced spine loss (8.9 ± 2.4 per 10 μm) (Fig 5B) . Inhibition of both purinergic receptors and VOCCs did not offer additional protection (7.5 ± 2.2 per 10 μm) compared with inhibition of VOCCs alone (Fig 5B) . These data demonstrate that the EFV metabolite 8-OH-EFV in the low nM range induces damage to dendritic spines.
Plasma and CSF concentrations of Efavirenz and 8-hydroxyefavirenz
We determined plasma and CSF concentrations of EFV and 8-OH-EFV in human subjects on stable cART regimens that included EFV. In these subjects the median plasma concentration of EFV was 2170 ng/ml (range 1010-7510), and JPET #195701 15 concentration of EFV was 18.8 ng/ml (range 6.28-52.9) and 3.37 (range 0.35-32.7) for 8-OH-EFV (Fig 6B) . These median values correspond to CSF concentrations of 59.6 nM for EFV and 10.2 nM for 8-OH-EFV.
DISCUSSION
Long-term cART has dramatically decreased the mortality rate of HIV-infected individuals, owing to the ability of these drugs to suppress viral replication. Most
ARVs do not enter into the CNS in appreciable amounts, and thus brain has remained a reservoir for HIV (Langford et al., 2006) . Ongoing (although likely low-level) viral replication in brain is thought to contribute to the pathogenesis of HAND (Masliah et al., 2000; Neuenburg et al., 2002; Langford et al., 2003) and targeting ARVs to inhibit viral replication in brain to treat or prevent HAND has been suggested (May et al., 2007) . However, this approach has raised concerns that some ARVs may damage neurons. Unfortunately, very little experimental data is available on the potential of ARVs or drug metabolites to damage neurons.
The CNS side effects of EFV that have been described include dizziness, vivid dreams, headaches, disturbances in attention and sleep, psychotic events and hallucinations, with the majority of these events regarded as mild. The most evident CNS side effects of EFV generally occur and resolve within the first month of therapy and rarely lead to discontinuation of the therapy (Moyle, 1999) .
However, recent data have associated EFV with a higher risk of neurocognitive impairment, particularly on tasks requiring a high degree of attention and
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16 executive function (Ciccarelli et al., 2011) . It has also been reported that cART regimens containing EFV may lead to a worsening of cognitive performance after several weeks of treatment (Winston et al., 2010) , and that these impairments in cognitive performance are significantly improved when patients discontinued treatment . As would be expected, the severity of these CNS symptoms correlates to EFV plasma concentrations (Marzolini et al., 2001) .
However not all studies have confirmed this relationship (Clifford et al., 2005) .
In this study we sought to directly determine the effects of EFV and its hydroxylated metabolites on neurons. Our findings suggest that 8-OH-EFV is atleast an order of magnitude more toxic to neurons compared to the parent compound EFV or 7-OH-EFV. Damage to dendritic spines was produced with 100 nM EFV or 7-OH-EFV. The 8-OH-EFV metabolite was approximately 10-fold more toxic compared to EFV and caused considerable dendritic damage10 nM with frank cell death at a 100 nM dose. We found that concentrations of EFV and 8-OH-EFV in CSF from human subjects taking cART appear to be within this neurotoxic dose range. The median concentration of EFV in the CSF of HIVinfected subjects taking cART-containing EFV was 59.6 nM, similar to previously reported CSF concentrations of 35 nM (0.5% of that in plasma) (Moyle, 1999; Tashima et al., 1999; Best et al., 2011) . The median concentration of 8-OH-EFV in CSF was 10.2 nM. Together these data suggest that concentrations of the parent drug EFV in brain may be within the range that can damage neurons, and that concentrations of 8-OH-EFV could be three times the minimal dose that produced dendritic damage to cultured neurons. Moreover, there may be a genetic susceptibility to the neurotoxic effects of EFV that is related to its rate of metabolism. Extensive EFV metabolizers were recently identified who express the *1/1 haplotype of CYP2B6 (Ngaimisi et al., 2010) . Thus, a genetic susceptibility in some individuals may exaggerate the neurotoxic effects of EFV due to a rapid metabolism of EFV with accumulations of the 8-OH-EFV metabolite.
This enhanced toxicity of 8-OH-EFV appears to be due to the ability of this metabolite to perturb calcium homeostasis. The 8-OH-EFV metabolite, but not 7-OH-EFV or the parent compound EFV induced rapid calcium influx in neurons that was partially inhibited by a general antagonist of purinergic receptors, and was almost completely eliminated by blockade of L-type VOCC. Calcium permeable NMDA and AMPA-type glutamate receptors were not activated by 8-OH-EFV. Consistent with a prominent role for VOCCs, inhibition of L-type calcium channels partially protected densritic spines from 8-OH-EFV-induced damage. These data suggest that the metabolism of EFV produces a highly neurotoxic metabolite (8-OH-EFV) that is capable of damaging neurites at very low concentration. Thus, cognitive impairments associated with EFV may involve synaptic damage mediated by its major metabolite 8-OH-EFV. It is interesting to note that the parent compound EFV, and the 7-OH-EFV metabolite also displayed a neurotoxic potential that appeared to be calcium-independent. The mechanisms of these separate toxic effects are currently being studied and may interact with the toxicity produced by 8-OH-EFV.
It is interesting that position of the OH group on the 7 vs 8 carbon of the benzoxazine ring produces such a dramatic difference in evoked calcium flux and neurotoxicity. These data suggest that the proximity of the OH group at position 8 to the nitrogen group in the benzoxazine structure is the critical determinant for forming a highly neurotoxic metabolite of EFV. Therefore, substituting the carbon at position 8 so that EFV cannot be hydroxylated at this position should produce a compound with decreased neurotoxicity. Such a drug with a fluorine substituent at carbon 8 which retains inhibitory activity at reverse transcriptase (with an IC 90 = 7.19 nM that is close to the IC 90 = 2.03 nM of EFV) has been synthesized (Patel et al., 1999) . This drug may offer an alternative to EFV with reduced neurotoxicity resulting from secondary metabolite production.
These findings contribute to our understanding of the mechanism for neurotoxicity associated with EFV therapy. Since the anticipated length of therapy for cART is the lifetime of the patient, these data highlight the importance of screening antiretroviral drugs and drug metabolites for neurotoxic potential.
This principle may be especially important if brain penetration is desired to reduce CNS viral replication.
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